Stockscreener 앱 받기
6.10
5.35%
0.31
Olema Pharmaceuticals Inc 주식(OLMA)의 최신 뉴스
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion - MSN
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,616 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $4,730,136.75 in Stock - MarketBeat
Olema Pharmaceuticals director Graham Walmsley sells $4.73m in stock - Investing.com
(OLMA) Technical Pivots with Risk Controls - Stock Traders Daily
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Bought by Wellington Management Group LLP - MarketBeat
Charles Schwab Investment Management Inc. Increases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
What is HC Wainwright’s Forecast for OLMA FY2024 Earnings? - Defense World
What is HC Wainwright's Estimate for OLMA FY2024 Earnings? - MarketBeat
Olema Pharmaceuticals stock hits 52-week low at $7.67 By Investing.com - Investing.com Canada
Olema Pharmaceuticals stock hits 52-week low at $7.67 - Investing.com India
Olema Pharmaceuticals CEO Sean Bohen sells shares worth $986,365 By Investing.com - Investing.com Nigeria
Olema Pharmaceuticals, Inc. announced that it has received $249.999225 million in funding from a group of investors - Marketscreener.com
Olema Pharmaceuticals director sells shares worth $147,955 By Investing.com - Investing.com Nigeria
Olema Pharmaceuticals CEO Sean Bohen sells shares worth $986,365 - Investing.com
Olema Pharma shares maintain buy rating on clinical study data By Investing.com - Investing.com UK
Olema Pharmaceuticals (NASDAQ:OLMA) Given "Buy" Rating at HC Wainwright - MarketBeat
Olema Pharmaceuticals Advances Breast Cancer Treatments - TipRanks
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium - The Manila Times
Olema Oncology Presents Updated Clinical Results for - GlobeNewswire
Olema's Breast Cancer Drug Shows Promising 81% PFS Rate in ESR1 Mutation Patients in Clinical Trial - StockTitan
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor - Marketscreener.com
Olema Pharmaceuticals Shares Rise 8.9% on FDA Approval of Cancer Drug Application - MarketWatch
Olema Oncology Announces FDA Clearance of Investigational - GlobeNewswire
Olema Pharma's Novel Cancer Drug OP-3136 Secures FDA Clearance for Clinical Trials - StockTitan
(OLMA) Proactive Strategies - Stock Traders Daily
Biotechnology Value Fund L.P. Reduces Stake in Olema Pharmaceuti - GuruFocus.com
Point72 Asset Management L.P. Has $44.03 Million Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals Awards Stock Options to New Employees in Cancer Drug Development Push - StockTitan
Novartis and Olema expand alliance with $250m to boost breast cancer trials - MSN
Novartis deal and $250 million set Olema on the way - The Pharma Letter
Olema Pharmaceuticals, Inc. announced that it expects to receive $249.999225 million in funding from a group of investors - Marketscreener.com
Olema Pharmaceuticals, Inc. announced that it expects to receive $180.954185 million in funding from a group of investors - Marketscreener.com
Olema: Cash Infusion And Supply Agreement With Novartis Carries Tide Forward (OLMA) - Seeking Alpha
The Business Case For Buying Olema Pharmaceuticals Inc (NASDAQ: OLMA) Stock Now - Stocks Register
Olema in deal with Novartis on Kisqali breast cancer combo collaboration - Seeking Alpha
Olema stock surges on Novartis deal and $250M private placement - Investing.com Australia
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement - Yahoo Finance
Dynamic Technology Lab Private Ltd Takes $238,000 Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Great Point Partners LLC Acquires 203,120 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Price Target at $27.00 - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Recommendation of “Buy” by Brokerages - Defense World
Olema Pharmaceuticals stock upgraded on strong trial data By Investing.com - Investing.com Canada
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium - The Manila Times
Olema Oncology to Present New Breast Cancer Treatment Data at SABCS 2024 - StockTitan
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up – Still a Buy? - Defense World
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap UpHere's Why - MarketBeat
Victory Capital Management Inc. Has $10.17 Million Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Acquired by Victory Capital Management Inc. - MarketBeat
Olema Pharmaceuticals stock hits 52-week low at $8.51 - Investing.com
Olema Pharmaceuticals stock hits 52-week low at $8.51 By Investing.com - Investing.com UK
2.88%
2.65%
자본화:
|
볼륨(24시간):